Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Not Due to Anti-mitochondrial AntibodiesShow others and affiliations
2020 (English)In: Frontiers in Medicine, E-ISSN 2296-858X, Vol. 7, article id 108Article in journal (Refereed) Published
Abstract [en]
Metabolic profiling studies have recently indicated dysfunctional mitochondria in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This includes an impaired function of pyruvate dehydrogenase complex (PDC), possibly driven by serum factor(s), which leads to inadequate adenosine triphosphate generation and excessive lactate accumulation. A reminiscent energy blockade is likely to occur in primary biliary cholangitis (PBC), caused by anti-PDC autoantibodies, as recently proposed. PBC is associated with fatigue and post-exertional malaise, also signifying ME/CFS. We herein have investigated whether ME/CFS patients have autoreactive antibodies that could interfere with mitochondrial function. We found that only 1 of 161 examined ME/CFS patients was positive for anti-PDC, while all PBC patients (15/15) presented significant IgM, IgG, and IgA anti-PDC reactivity, as previously shown. None of fibromyalgia patients (0/14), multiple sclerosis patients (0/29), and healthy blood donors (0/44) controls showed reactivities. Anti-mitochondrial autoantibodies (inner and outer membrane) were negative in ME/CFS cohort. Anti-cardiolipin antibody levels in patients did not differ significantly from healthy blood donors. In conclusion, the impaired mitochondrial/metabolic dysfunction, observed in ME/CFS, cannot be explained by presence of circulating autoantibodies against the tested mitochondrial epitopes.
Place, publisher, year, edition, pages
Frontiers Media S.A., 2020. Vol. 7, article id 108
Keywords [en]
myalgic encephalomyelitis; chronic fatigue syndrome; anti-pyruvate dehydrogenase complex antibodies; PDC; anti-mitochondrial autoantibodies; AMA
National Category
Rheumatology and Autoimmunity
Identifiers
URN: urn:nbn:se:liu:diva-165479DOI: 10.3389/fmed.2020.00108ISI: 000526870400001PubMedID: 32296708Scopus ID: 2-s2.0-85083316140OAI: oai:DiVA.org:liu-165479DiVA, id: diva2:1428254
Note
Funding Agencies|Swedish ME Association; Solve ME/CFS; Swedish Cancer Association; Open Medicine Foundation (OMF)
2020-05-052020-05-052024-01-29Bibliographically approved